HeiScreen Preps Liquid Biopsy Breast Cancer Test for Year-End Launch

Mar 12, 2019

|

Premium

NEW YORK (GenomeWeb) — HeiScreen, a German molecular diagnostics company, is moving ahead with plans to introduce a liquid biopsy-based test for breast cancer detection for clinical use by the end of the year.

The company's assay relies on a set of 15 methylation and microRNA markers to determine whether a woman has breast cancer. HeiScreen is in the process of obtaining CE-IVD marking for the test with the aim of making it available to German clinicians later in 2019.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Breaking News

Jul

30

Featured Webinar

Single-Cell Sequencing Reveals Clonal Heterogeneity in Acute Lymphoblastic Leukemia

This webinar will outline a project that performs large-scale and integrative single-cell genome and transcriptome profiling of pediatric acute lymphoblastic leukemia (ALL) cases at diagnosis, during drug treatment, and in case of relapse.

Jul

31

Featured Webinar

Considerations and Impact of Implementing Targeted NGS in Myeloid Malignancies

This webinar will provide a first-hand look at how a molecular laboratory validated and implemented a targeted next-generation sequencing-based myeloid assay to expedite the assessment of myeloid malignancies and assist in the understanding of myeloid cancers.

Menu